Yuanqi forest's self built factory plans to invest 5.5 billion yuan with a total capacity of more than 5 billion bottles

IntoCare Zhang Hui: Ingenuity Forges Quality, Continuous Improvement Safeguards Lives

In 2024, nearly all medical enterprises are exploring overseas markets. This trend is driven by an anti-corruption wave within the medical industry, the demand for financing and initial public offerings, as well as challenges such as excess production capacity. Presently, venturing abroad has become an essential developmental path for medical device enterprises. Successfully entering foreign markets is not only a crucial means for the medical industry to achieve a second grow

Sino Biopharm and Boehringer Ingelheim Sign Option and License Deal for Six Cancer Programs

Sino Biopharmaceutical（中国生物制药）and Boehringer Ingelheim（勃林格殷格翰）announced an option and license agreement on November 4 covering six preclinical cancer programs. Sino Biopharm will receive USD 358 million in upfront and near-term payments and may receive up to USD 7 billion in additional option, development, regulatory and commercial milestone payments.

Wantai Launches Nine-Valent HPV Vaccine Cecolin 9 in Thailand

Wantai Biological（万泰生物）said on November 2 that its nine-valent HPV vaccine, Cecolin 9（馨可宁9）, had launched in Thailand. The product was jointly developed by its subsidiary Xiamen Innovax Biotech（厦门万泰沧海生物技术有限公司）and Xiamen University（厦门大学）.

Futurtec Adds CE MDR-Certified Knee-Replacement System to Its Orthopedic Robotics Portfolio

Futurtec（鑫君特）has received European Union Medical Device Regulation certification for its ORTHBOT X knee-replacement surgical navigation and positioning system, according to a company announcement reported by MedChina in August.

EqualOcean Presents: China Big Tech Crackdown Winners

This research report gathers all the information you need to understand the recent antitrust regulation shifts in China and analyzes ten companies that are likely to win big from them.